D86.9
Conditions
Interventions
Group 1: Sarcoidosis patients without atrial cardiomyopathy (as assessed in ECG or TTE)
Group 2: Sarcoidosis patients with atrial cardiomyopathy (as assessed in ECG or TTE)
Sponsors
Universitätsklinikum Freiburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male and female patients aged =18 years with sarcoidosis 2. Written informed consent for study participation prior to enrollment 3. Ability to understand the nature of the trial and the trial related procedures and to comply with them
Exclusion criteria
Exclusion criteria: 1. Prior cardiac surgery or left atrial catheter ablation 2. No sinus rhythm to perform ECG or transthoracic echocardiography in sinus rhythm at study inclusion 3. Severe valvular heart disease (mitral or aortic valvulopathy >Grade 2/3)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Prevalence of an atrial cardiomyopathy (ACM) in patients with sarcoidosis assessed by the amplified P-wave analysis (aPWA). | — |
Secondary
| Measure | Time frame |
|---|---|
| - Prevalence of an atrial cardiomyopathy (ACM) in patients with sarcoidosis assessed by echocardiography parameters (left atrial emptying fraction (LA-EF), left atrial strain (LAS)). - Prevalence of atrial fibrillation (AF) and heart failure in sarcoidosis patients with and without ACM - Association between ACM and pulmonary capillary wedge pressure and pulmonary artery pressure in a subgroup of patients with sarcoidosis undergoing right heart catheterization - Association between ACM and left and right atrial and right and left ventricular strain in patients with sarcoidosis - Association between ACM and NT-proBNP in patients with sarcoidosis - Association between ACM and quality of life - Association of pharmacological and non-pharmacological treatment for sarcoidosis and findings in imaging and ECG, lung function, cardiac function, biomarkers and quality of life - Association of ACM and the prevalence of sleep-associated breathing disorder in COPD and sarcoidosis - Association of ACM on mortality of patients with COPD and sarcoidosis in general and after lung transplantation - Association of ACM and atrial FDG uptake or late Gadolnium enhancement (LGE) in a subgroup of patients with sarcoidosis who underwent or undergo PET/CT or cardiac MRI - Prevalence of ACM in sarcoidosis patients with and without cardiac involvement - Comparison of different diagnostic tools for sarcoidosis (ECG, TTE, MRI, PET-CT, biomarkers) regarding sensitivity and specificity for diagnosis and outcome (e.g. heart failure, any arrhythmias, mortality, syncope, lung function, cardiac function, health status) in patients with sarcoidosis with and without cardiac involvement/atrial cardiomyopathy - Identification of specific imaging patterns for diagnosis and outcome using artificial intelligence - Association of different phenotype clusters of organ involvement with outcome in patients with sarcoidosis - Identification of protein candidates/biomarkers for bo | — |
Countries
Germany
Contacts
Public ContactMartin Eichenlaub
Universitätsklinikum Freiburg, Klinik für Kardiologie und Angiologie
Outcome results
None listed